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indication of comedonal and papulopustular acne sever-
ity, respectively. Furthermore, these measurements may be 
more sensitive and specific in evaluating treatment effects 
and early signs of acne lesion progression compared to 
investigators’ lesion counts.
Keywords Coproporphyrin III · Protoporphyrin 
IX · Fluorescence imaging · Acne assessment · Acne 
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Introduction
The pathogenesis of acne is multifactorial with four pri-
mary factors: (1) increased sebum production, (2) altera-
tions in the keratinization process, (3) Propionibacterium 
acnes (P. acnes) follicular colonization, and (4) release of 
inflammatory mediators [5, 6, 15, 19, 27]. Excess keratin 
combined with sebum partially obstructs the opening of 
the follicle forming a microcomedo which is the begin-
ning of comedonal lesion development [21]. Since there is 
no identifiable feature visible on the skin surface, the early 
clinical detection and evaluation of treatment effects at 
this stage are not possible. Acne lesions, including come-
donal lesions, are colonized by P. acnes. These bacteria 
produce pro-inflammatory mediators which contribute to 
the development of visible papulopustular lesions [4, 5]. 
Traditionally, papulopustular acne lesions were considered 
inflammatory, while the comedonal lesions were consid-
ered non-inflammatory. However, recent data have clearly 
shown a role for inflammation at all stages of acne lesion 
development, perhaps, sub-clinically even before comedo 
formation [25].
In clinical research, Investigator Global Assessment 
(IGA) scales are widely used for assessing overall acne 
Abstract Propionibacterium acnes: (P. acnes) produce 
Porphyrins; however, fluorescence measurement of Por-
phyrins from Ultraviolet-A (UVA) images has failed to 
establish a correlation. Acne clinical research and imag-
ing has ignored the spectral excitation-emission character-
istics and the exact pattern of the Porphyrins synthesized 
by P. acnes. In this exploratory study, for the first time, the 
possible relationships of Coproporphyrin III (CpIII) and 
Protoporphyrin IX (PpIX) fluorescence as well as acne 
lesion-specific inflammation measurements with clinical 
signs of acne are investigated. Furthermore, the sensitivity 
of these measurements in tracking and differentiating the 
known treatment effects of Benzoyl Peroxide (BPO) 5%, 
and combination of Clindamycin + BPO are also evaluated. 
Comedonal and papulopustular lesions identified by inves-
tigators during a live assessment of 24 mild-to-severe acne 
subjects were compared with fluorescence and inflamma-
tion measurements obtained from analysis of  VISIA®-CR 
images. CpIII fluorescence spots showed a strong correla-
tion (r = 0.69–0.83), while PpIX fluorescence spots showed 
a weak correlation (r = 0.19–0.27) with the investigators’ 
comedonal lesion counts. A strong correlation was also 
observed between the investigators’ papulopustular lesion 
counts and acne lesion-specific inflammation (r = 0.76). 
Our results suggest that CpIII fluorescence and acne lesion-
specific-inflammation measurement can provide objective 
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severity, although interrater reliability may be low. Acne 
manual lesion counting is another approach. It allows 
researchers to differentiate between papules, pustules, 
open comedones, and closed comedones; however, 
reproducibility is limited [24]. An objective measure-
ment technique that can quantify acne severity and is 
sensitive and specific in tracking treatment effectiveness 
may, therefore, be advantageous.
Several studies have reported analysis of Porphyrins 
with UVA excited fluorescence images for acne evalua-
tion, but with limited success [1, 9, 13, 14]. In general, 
the imaging systems combine a UVA light source with 
a digital colour camera to capture a fluorescence image. 
The fluorescence signal is evaluated based on its colour 
rather than its spectral nature. Furthermore, instead of 
using a specific filter, the UVA blocking filter within the 
camera is assumed to block the excitation light. These 
studies report measuring Porphyrin fluorescence from 
the red colour channel and ignore the fluorescence in 
green and blue colour channels. The fluorescence sig-
nal in the red channel is mostly from Protoporphyrin IX 
(PpIX) (emission > 630 nm), while the Porphyrin mainly 
produced by P. acnes bacteria is Coproporphyrin III 
(CpIII) with greenish-orange (570–630 nm) fluorescence 
[7, 8, 10, 14, 17, 20, 23]. The green channel fluorescence 
is attributed to horn (aggregated follicular corneocytes) 
and was suggested for evaluating comedones [9]. How-
ever, the molecular nature, composition, and spectral 
response of horn are unknown.
Measurement of fluorescence and acne inflammation 
is possible using  VISIA®-CR images (Canfield Scien-
tific, Inc.). VISIA-CR uses high-power xenon strobes to 
excite Porphyrins at their absorption peak (405 ± 10 nm) 
and specific spectral filters in front of the camera for 
separation of PpIX and CpIII fluorescence signals. For 
quantitative fluorescence measurement, the captured 
fluorescence images are corrected for non-uniform light 
distribution and tissue absorption using the excitation 
light reflectance image [16]. Acne lesion-specific inflam-
mation (acne-spots) is detected and measured from the 
 RBX®-Red images. RBX transformation [3] allows 
separation of haemoglobin (Red) and melanin (Brown) 
absorption from the cross-polarized images using a 
spectro-colourimetric light-tissue interaction model.
The overall research question of this explorative 
study was whether, and how, CpIII and PpIX fluores-
cence measurements and RBX-Red based acne-spot 
measurements are associated with clinical signs of 
acne. Sensitivity of these measurements in tracking 
and differentiating the known treatment effects of BPO 
5%, and combination of Clindamycin + BPO were also 
investigated.
Materials and methods
Prior to conducting any study procedures, this study was 
approved by the independent Ethics Committee of the State 
Office of Health and Social Affairs Berlin. The study was 
registered at the European Union Drug Regulating Authori-
ties Clinical Trials Database (EudraCT 2013-001716-30; 
https://eudract.ema.europa.eu/). The study was conducted 
according to the principles of the Declaration of Helsinki 
(1996) and Good Clinical Practice Guidelines (1996).
The data presented here was generated as part of an 
exploratory study to investigate the efficacy and tolerabil-
ity of Tyrothricin 0.1%, an Anti-microbial Peptide (AMP), 
compared to two established topical acne treatments, 
namely Benzoyl Peroxide (BPO) 5% and combination of 
Clindamycin + BPO. The results of this investigation are 
reported elsewhere [18].
In total, 24 male and female non-smoking patients aged 
18–24 years with a diagnosed mild-to-severe papulopus-
tular acne, defined as having an Investigator Global Static 
Assessment (IGSA) [22, 28] score of 2–4, were included 
after giving their written informed consent. Patients were 
randomized with regard to treatment and facial side allo-
cation. Using a split-face design, 12 out of the 24 patients 
received Benzoyl Peroxide (BPO) 5%  (Aknefug®Oxid mild 
5%, Dr. August Wolff GmbH & Co.KG Arzneimittel, Biele-
feld, Germany), and the remaining 12 patients received a 
combination of Clindamycin + BPO  (Duac®Akne Gel, 
GlaxoSmithKline GmbH and Co. KG, Berlin, Germany) 
on half of their face. All 24 patients received Tyrothricin 
0.1%  (Tyrosur®Gel, Engelhard Arzneimittel GmbH and 
Co. KG, Niederdorfelden, Germany) on the other half of 
their face. Papulopustular and comedonal lesion counting 
was performed manually by blinded investigators through 
live assessment of the subjects pre-treatment (Baseline) and 
post-treatment (Day 12 and Day 25).
Multi-modality facial images of the subject’s frontal, 
left-side, and right-side views were captured at Baseline, 
Day 12, and Day 25 using the VISIA-CR. The captured 
images included the following lighting modalities: Stand-
ard White Light Image (Clinical Photograph), Standard 
White Flat-Lit Image (Analysis Image), Cross-Polarized 
Image (Diffuse Reflectance Image), Parallel-Polarized 
Image (Surface Reflectance Image), PpIX Fluorescence 
Image, CpIII Fluorescence Image, and Excitation Light 
Reflectance Image. During live assessment of the subjects, 
the imaging system allowed the investigators to annotate 
the locations of the identified lesions on the photographs 
displayed on the screen. X–Y locations of all marked 
lesions along with the lesion type were saved into the sub-
ject’s record.
All captured images were analysed while blinded to the 
patient’s treatment and facial side randomization, as well as 
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the investigators’ lesion counts and lesion locations. Anal-
ysis of images started by elastically registering the multi-
modality images captured during a particular session with 
respect to the cross-polarized image captured during that 
session [26]. Cross-polarized images were transformed into 
RBX-Red and Brown images, while the CpIII and PpIX 
fluorescence images were corrected for heterogeneous tis-
sue absorption using the excitation reflectance images. 
Fig. 1  Split-face area-of-
interest (AOI): As illustrated 
in mannequin images, the 
measurements for the left- and 
right-side views are added to 
the measurements from the 
corresponding half side of the 
forehead to obtain the split-face 
study data
Fig. 2  Acne lesions and associ-
ated Porphyrin fluorescence and 
inflammation measurements: 
left view images of a subject 
showing the comedonal lesions 
(white circles) and papulo-
pustular lesions (blue circles) 
identified by the investigator on 
a standard 1 image showing the 
AOI (green outline), b corrected 
Coproporphyrin III (CpIII) fluo-
rescence image with detected 
fluorescence spots (green dots), 
c corrected Protoporphyrin IX 
(PpIX) fluorescence image with 
detected fluorescence spots 
(pink dots), and d RBX-red 
image showing detected acne-
specific inflammation (acne-
spots) (red outline)
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Area-of-Interest (AOI) for analysis was then delineated, as 
illustrated in Fig. 1, using facial landmarks to include the 
chin, cheek, and temple regions of the face in the left- or 
right-side view images, and the forehead in the front-view 
image. The subject’s nose was not included in the AOIs. 
The forehead AOI was further split horizontally into left 
and right forehead zones.
CpIII and PpIX fluorescence spots were detected irre-
spective of their size and intensity from the corrected fluo-
rescence images, while the acne-spots were detected from 
the RBX-Red images. For all detected features, the frac-
tional area of the detected spots with respect to the area 
of the AOI was measured. For the fluorescence spots, the 
detection algorithm reported individual spot areas and 
their X–Y locations. A median fluorescence spot size was 
calculated for each individual subject using the Baseline 
measurements. The detected fluorescence spots were then 
filtered to retain those that were larger than a fixed pre-
determined threshold.
Baseline (pre-treatment) data from all subjects were 
used to evaluate the relation between image analysis-based 
measurements and investigator assessed lesion counts. 
Pearson’s correlation coefficients were calculated to esti-
mate the association of fractional areas of the fluorescence 
spots with the comedonal lesion counts, as well as the 
fractional areas of the acne-spots with the papulopustular 
lesion counts.
In the auto-classification technique, large fluorescence 
spots and acne-specific inflammation were the main fea-
tures used in classifying the comedonal and papulopustu-
lar lesions, respectively [16]. Using the Baseline measure-
ments, the association of the area of the fluorescence spots 
with respect to the investigators’ comedonal lesions was 
evaluated. For this, the total number of fluorescence spots 
that were larger than a fixed threshold value was compared 
Fig. 3  Scatter plots: a comedonal lesion counts versus fractional 
area with CpIII fluorescence spots within the AOI (n = 44, r = 0.45, 
p value < 0.01), b comedonal lesion counts versus fractional area 
with PpIX fluorescence spots within the AOI (n = 44, r = 0.21, p 
value = 0.16), and c papulopustular lesion counts verses fractional 
area of lesion-specific inflammation (n = 44, r = 0.76, p value < 0.001)
Fig. 4  Typical facial distribu-
tion of Porphyrins: a CpIII 
fluorescence image and b PpIX 
fluorescence image of a subject 
show that the PpIX fluorescence 
spots are mainly localized in the 
T zone and area surrounding the 
nose, while the CpIII fluo-
rescence spots can be located 
anywhere on the subject’s face
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with the investigators’ comedonal lesion counts. The range 
of threshold values evaluated were 60–140% of the sub-
ject’s median fluorescence spot size.
The X–Y locations of detected fluorescence spots from 
the subject’s images were compared with the X–Y loca-
tions of the subject’s acne lesions identified and annotated 
by the investigators. If a fluorescence spot was identified 
inside a one millimetre (1 mm) diameter circle centered at 
the X–Y location of the investigators’ identified lesion, it 
was considered a match. A percentage of comedonal and 
papulopustular lesions with co-located fluorescence spots 
were calculated for all subjects. Semantic comparison was 
also used to establish and verify the association between 
the detected spots and the investigators’ identified lesions. 
Similar comparison was done between the acne-spots and 
the subject’s acne lesions identified and annotated by the 
investigators.
The presence of fluorescence signal suggests P. acnes 
bacterial colonization in a follicular unit. However, dur-
ing clinical evaluation, some of this bacterial activity is 
not accounted for due to the absence of visual skin surface 
indicators. This may result in lowering the sensitivity of 
measuring the treatment effect or delaying the evaluation. 
Hence, instead of using filtered fluorescence measurement, 
we measured the treatment effect as a percent change in the 
fractional area of all of the detected fluorescence spots. For 
similar reason, treatment effects on papulopustular lesions 
were measured as a percent change in the fractional area 
of all of the acne-spots. The percent change was meas-
ured on both Day 12 and Day 25 with respect to Baseline 
for the subject’s facial side treated either with BPO 5% or 
Clindamycin + BPO. These two measurements were com-
pared with clinical treatment efficacy measured as a per-
cent change in investigators’ comedonal and papulopus-
tular lesion counts on Day 12 and Day 25 with respect to 
Baseline.
Results
The lesions annotated by the investigator on the subject’s 
clinical image are illustrated in Fig.  2a. The association 
of CpIII fluorescence spots, PpIX fluorescence spots, and 
acne-spots with the investigator-annotated acne lesions can 
be seen in Fig. 2b–d, respectively.
When comparing the investigators’ comedonal lesion 
counts with the number of CpIII fluorescence spots fil-
tered using area dependent thresholds, the correlation 
coefficients ranged from 0.69 to 0.83. Figure  3a shows 
the scatter plot of the comedonal lesion counts versus the 
fractional area of all CpIII fluorescence spots. The cor-
relation coefficient between the investigators’ comedonal 
lesion counts and the fractional area of all detected CpIII 
fluorescence spots was 0.45 (n = 44). When the loca-
tions of these fluorescence spots were compared with 
the locations of the investigators’ identified lesions, 94% 
open comedones and more than 70% of the closed come-
dones exhibited CpIII fluorescence signals. The inten-
sity of the CpIII fluorescence spots was very high with 
a well-defined circular boundary for open comedones. 
For closed comedones, the CpIII fluorescence spots had 
a lower intensity and appeared diffused. About 20% of 
the papulopustular lesions also exhibited a CpIII fluores-
cence signal. The intensity of this signal was observed 
to be dependent on the haemoglobin concentration sur-
rounding the lesions.
Figure  3b shows the scatter plot of comedonal lesion 
counts versus the fractional areas of all PpIX fluorescence 
spots. The correlation coefficient between the investiga-
tors’ comedonal lesion counts and the fractional area of 
all detected PpIX fluorescence spots was 0.21 (n = 44). 
When comparing the locations of these fluorescence spots 
with the locations of the investigators’ identified lesions, 
less than 15% of the comedonal lesions exhibited PpIX 
fluorescence signal. When comparing the comedonal 
lesion counts with the number of PpIX fluorescence spots 
filtered using area dependent thresholds, PpIX fluores-
cence spots showed no particular relationship with the 
investigators’ comedonal lesion counts. The correlation 
Table 1  Mean percent change in acne lesion counts and fractional 
areas of Coproporphyrin III (CpIII)/Protoporphyrin IX (PpIX) fluo-
rescence spots and acne-specific inflammation (acne-spots) due to 
treatment
Comparison of the mean percent change (n = 11) and standard devia-
tion (SD) in the fractional area of fluorescence spots and acne-spots 
with the percent change in the investigators’ comedonal and papulo-
pustular lesion counts at Day 12 and Day 25 with respect to Baseline 
for the Clindamycin + BPO and BPO 5% treatment groups
Time point Clindamycin + BPO BPO 5%
Mean SD Mean SD
Change in comedonal lesion count (%)
Day 12 −18.13 46.01 −29.01 29.82
Day 25 −42.93 19.50 −47.04 27.97
Change in fractional area of CpIII fluorescence spots (%)
Day 12 −70.38 33.73 −67.49 30.47
Day 25 −71.67 35.82 −49.54 24.30
Change in fractional area of PpIX fluorescence spots (%)
Day 12 −43.60 15.76 −63.68 8.25
Day 25 −51.21 17.46 −64.10 7.01
Change in papulopustular lesion count (%)
Day 12 −39.83 32.21 −29.15 23.38
Day 25 −53.25 32.39 −50.75 18.44
Change in fractional area of acne spots (%)
Day 12 −10.50 14.63 0.60 13.80
Day 25 −18.57 9.77 −7.11 15.46
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coefficients ranged between 0.19 and 0.27 for threshold 
values ranging 60–140% of the subject’s median fluores-
cence spot size. Unlike the scattered facial distribution of 
the CpIII fluorescence spots, visual inspection of images 
revealed that the PpIX fluorescence spots were mainly 
distributed in the T zone and in the area surrounding the 
subject’s nose. Figure  4 shows front-view fluorescence 
images of a subject illustrating the typical facial distribu-
tion of CpIII and PpIX fluorescence spots.
Figure 3c shows the scatter plot of papulopustular lesion 
counts versus the fractional area of detected acne-spots. 
The correlation coefficient between the investigators’ pap-
ulopustular lesion counts and the fractional area of acne-
spots was 0.76 (n = 44). When comparing the locations, 
almost all of the investigators’ identified papulopustular 
lesions were located within the detected acne-spots.
Table 1 shows the mean percent change and the associ-
ated standard deviation for all the measurements at Day 12 
and Day 25 with respect to Baseline for the two treatment 
groups. Figure  5 a, b shows the changes in the investiga-
tors’ comedonal lesion counts compared to the changes in 
fractional areas of CpIII and PpIX fluorescence spots, 
respectively. Figure 5c shows the change in the investiga-
tors’ papulopustular lesion counts compared to the change 
in fractional area of acne-spots.
When comparing the average percent change in the 
investigators’ comedonal lesion counts with respect to 
Baseline, at Day 12, BPO 5% showed about 10% more 
reduction compared to Clindamycin + BPO. However, 
at Day 25, no differences were observed between the two 
treatment groups. When comparing the average percent 
change in the fractional area of CpIII fluorescence spots, 
both treatments at Day 12 showed a reduction in the fluo-
rescence measurement by about 70%. However, at Day 25, 
while Clindamycin + BPO continued to maintain almost the 
same amount of reduction, the reduction due to BPO 5% 
alone lowered to about 50%. When comparing the percent 
change in the fractional area of PpIX fluorescence spots, 
BPO 5% showed a stronger reduction compared to Clinda-
mycin + BPO at both Day 12 and Day 25.
When comparing the average percent change in the 
investigators’ papulopustular lesion counts with respect 
to Baseline, at Day 12, Clindamycin + BPO showed about 
10% more reduction compared to BPO 5%. However, at 
Day 25, no significant differences were observed between 
the two treatment groups. When comparing the percent 
change in the fractional area of acne-spots between the 
treatment groups, Clindamycin + BPO showed a stronger 
reduction on both Day 12 and Day 25 compared to BPO 
5%, with BPO 5% showing almost no change at Day 12 
with respect to Baseline.
Figure  6 shows cropped Clinical, RBX-Red, and CpIII 
fluorescence images of a subject’s cheek area from the side 
treated with the combination product Clindamycin + BPO 
at Baseline and Day 25. Cropped higher resolution images 
are shown here to illustrate the clinical treatment effect and 
the associated change in the acne-specific inflammation 
(acne-spots) and CpIII fluorescence.
Discussion
For decades, acne imaging research has focused on col-
our rather than the spectral nature of the porphyrin fluo-
rescence signal [1, 9, 14]. The red fluorescence and green 
fluorescence seen in a UVA image have been generalized as 
porphyrin and horn fluorescence, respectively. VISIA-CR 
allows separation and measurement of CpIII and PpIX fluo-
rescence signals when capturing full-facial images of acne 
subjects. In this study, for the first time, we have shown 
associations of CpIII fluorescence with comedonal lesions. 
An association between CpIII fluorescence and papulopus-
tular lesions could not be observed because the fluores-
cence signal is strongly absorbed by the surrounding hae-
moglobin. However, an association of the lesion-specific 
inflammation (acne-spots) measurement obtained from 
RBX-Red images with the papulopustular lesions could be 
demonstrated. Our results suggest that these two measure-
ments may provide specific assessments of acne severity.
We have evaluated the area distribution of the CpIII flu-
orescence signal as a fractional area measurement, as well 
as the total count, size, and intensity of the individual spots. 
The number of fluorescence spots filtered, based on their 
size, showed high correlations with the clinically visible 
comedones and justifies its use as the main feature in for-
mulating a classification method reported earlier [16]. Even 
though the correlation coefficient was lower when compar-
ing all of the detected fluorescence spots, a clear associa-
tion between this measurement and clinical assessment was 
demonstrated. As evident from the treatment efficacy, this 
measurement may be more sensitive and specific in detect-
ing varying effects based on different modes of treatment 
[2, 11, 12]. This may be attributed to the early indication 
of colonizing bacteria and treatment effect on emerging 
lesions. Since CpIII is produced by colonizing P. acnes 
bacteria, imaging and measuring this fluorescence signal 
Fig. 5  Treatment effect and its directionality: average percent change 
in investigators’ lesion counts and image analysis-based measure-
ments at Day 12 and Day 25 with respect to Baseline for BPO 5% 
and Clindamycin + BPO treatment groups: a investigators’ comedonal 
lesion counts compared to fractional area of CpIII fluorescence spots, 
b investigators’ comedonal lesion counts compared to fractional 
area of PpIX fluorescence spots, and c investigators’ papulopustular 
lesion counts compared to fractional area of acne-specific inflamma-
tion (acne-spots). No significant difference in the investigators’ lesion 
counts was noted between the two treatment groups
◂
166 Arch Dermatol Res (2017) 309:159–167
1 3
should provide a severity indication of the clinically visible 
comedones as well as the pre-clinical microcomedones. 
Furthermore, if the treatment stops P. acnes bacterial 
growth/colonization, the reduced concentration of CpIII 
will reflect in the fluorescence signal and provide an effi-
cacy measurement to the anti-microbial treatment.
Our results indicate a strong association between the 
investigators’ papulopustular lesion counts and the frac-
tional area of acne-spots detected from the RBX-Red 
images. An auto-lesion classification system using this 
feature as one of the primary identifiers of papulopustu-
lar lesions has already been reported [16]. The acne-spot 
detector identifies circular haemoglobin concentrated areas 
and not the global redness or background redness due to 
treatment reaction. Although the detection may include 
both active and residual erythema, differentiating between 
the two is also challenging during clinical assessment. An 
anti-inflammatory treatment should prevent or reduce the 
number of comedones evolving into papulopustular lesions 
and reduce the inflammation of existing lesions. This treat-
ment effect will reflect in the acne-spots fractional area 
measurement. Furthermore, since a self-evaluating patient 
is primarily focused on the acne-spots, this measurement 
may also relate better with patient-assessed outcomes. 
Using the fractional area of CpIII fluorescence spots and 
acne-spots as objective measures of comedonal and papulo-
pustular lesion, severity, respectively, in interventional acne 
research can, therefore, be promising and beneficial.
Our data indicate weaker associations between spot size, 
location, and/or intensity of PpIX fluorescence signal with 
acne lesions. However, PpIX fluorescence also needs to 
be reevaluated in studies involving δ-aminolaevulinic acid 
(ALA) and the methyl ester of ALA (MAL). ALA or MLA 
taken up by P. acnes can result in an increased concentra-
tion of endogenous porphyrins, and in some colonies, a 
predominance of PpIX can be observed [8]. Furthermore, 
the facial distribution of PpIX mainly in areas with higher 
sebum production rate suggests a need to investigate the 
association between two.
In addition to providing indications of comedonal and 
papulopustular acne severity, measurement of the associa-
tion between CpIII/PpIX and acne lesion-specific inflam-
mation may be more sensitive and specific to treatment 
effects and the early signs of lesion progression. Being 
simple and objective, these quantitative measurements can 
be translated from clinical research to clinical practice. 
The higher sensitivity of these measurements in evaluating 
treatment efficacy can benefit phase-II dose-ranging clini-
cal studies.
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Fig. 6  Change in acne sever-
ity and corresponding change 
in the CpIII fluorescence and 
acne-spots due to treatment: a, 
d Clinical, b, e RBX-Red, and 
c, f CpIII fluorescence cropped 
images showing a region of the 
subject’s face treated with the 
combination product Clinda-
mycin + BPO at Baseline and 
Day 25
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